JBPOS 0101
Alternative Names: ADD-417090; JBPOS-0101Latest Information Update: 28 Apr 2024
At a glance
- Originator BioPharm Solutions
- Class Antidementias; Antiepileptic drugs; Phenylcarbamates
- Mechanism of Action Metabotropic glutamate receptor 7 antagonists; Metabotropic glutamate receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy; Infantile spasms
- No development reported Alzheimer's disease; Status epilepticus
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Status-epilepticus in USA (IV, Injection)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral, Injection)